2024. Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s419. DOI:https://doi.org/10.25251/skin.8.supp.419.